Therapeutic monoclonal antibodies, which target TNF-α (adalimumab, etanercept, and infliximab) or the p40 subunit of IL-12 and IL-23 (e.g., UST), have become pivotal in managing severe psoriasis and are generally well tolerated. Here, TNF is linked to psoriasis.